Summary:
Click image to enlargeThe purpose of this study is to see if the investigational study drug – a new generic candidate fluticasone propionate/salmeterol xinafoate inhalation powder – works the same as the already approved Advair Diskus® powder inhaler and better than placebo (an inactive material that will be packaged in an inhaler that looks the same as the study drug). A generic drug is a drug that is the same as a brand-name drug but it doesn’t have the brand name. An example of a generic drug is ibuprofen which has several brand names including Advil and Motrin. The study drug contains the same active ingredients at the same dosages as the Advair Diskus powder inhaler, fluticasone propionate and salmeterol. "Investigational" means the formulation being tested has not been approved by the FDA.
Qualified Participants Must:
• Be at least 12 years or older
•
Have had asthma for at least 12 weeks
•
Be a current non-smoker
•
Have not use tobacco products within the past year
•
Have a less than 10 pack year history of smoking
•
Be able to discontinue controller asthma medication during the study
Qualified Participants May Receive:
There will be no charge for your participation in the study. Medication provided as part of the study will be at no charge. You may receive up to $250 for being in this study. You will get $50 for completion of Visit 1, $150 for completion of Visit 2 and $50 for completion of Visit 3.
You will be responsible for some expenses for participation in this study, such as those for transportation to and from the site and/or parking.